|

Nivolumab Clinical Trials

163 actively recruiting trials across 53 locations

▼ -6 trials since June 2026

Also known as: 946414-94-4, ABP 206, Anti-PD-1, BCD-263, BMS 936558 +23 more

Pipeline

Early 1: 5Phase 1: 27Phase 2: 72Phase 3: 17Phase 4: 3Phase 1/2: 28Phase 2/3: 5

Top Sponsors

  • National Cancer Institute (NCI)14
  • Bristol-Myers Squibb7
  • The Netherlands Cancer Institute6
  • M.D. Anderson Cancer Center6
  • Washington University School of Medicine5

Indications

Other46 trials

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
Phase 2
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
N/A
A Study of TRK-950 in Patients With Advanced Solid Tumors
Phase 1/2
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Phase 1/2
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma
Phase 2
Agnostic Therapy in Rare Solid Tumors
Phase 2
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Phase 2
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
Phase 2
CARE1 Pragmatic Clinical Trial
Phase 3
CD8 PET Imaging in Metastatic Solid Tumours
Phase 2
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Phase 4
Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
Phase 2
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
Phase 2
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Phase 3
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
Phase 1/2
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Phase 4
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
Phase 2
Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
Phase 1
Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients
Phase 2
Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
N/A
Immunotherapy in Patients With Early dMMR Rectal Cancer
Phase 2
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Phase 1/2
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
Phase 2
Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)
Phase 1
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
Phase 2
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Phase 2
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
Phase 2
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Phase 2
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
Phase 2
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Phase 2
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
Phase 2
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Phase 2
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
Phase 2
Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
Phase 3
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
N/A
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Phase 2
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
Phase 2
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Phase 3
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Sagittarius Trial
Phase 3
Towards Cure Via Only Ultra-short ICB in CSCC
Phase 2
Using ctDNA to Determine Therapies for Lung Cancer
Phase 2

Birmingham, Alabama14 trials

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Children's Hospital of Alabama

Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 2
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Children's Hospital of Alabama

Phase 3
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

University of Alabama at Birmingham Cancer Center

Phase 2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1/2
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

University of Alabama at Birmingham

Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

University of Alabama at Birmingham Cancer Center

Phase 2
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

University of Alabama at Birmingham Cancer Center

Phase 1
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

University of Alabama at Birmingham Cancer Center

Phase 2
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

University of Alabama at Birmingham Cancer Center

Phase 1
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

University of Alabama at Birmingham Cancer Center

Phase 2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)

Phase 2
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

University of Alabama at Birmingham Cancer Center

Phase 3

Phoenix, Arizona7 trials

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Local Institution - 0284

Phase 2/3
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Mayo Clinic Hospital in Arizona

Phase 2
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

St. Joseph's Hospital and Medical Center

Phase 3
FOG-001 in Locally Advanced or Metastatic Solid Tumors

Mayo Clinic

Phase 1/2
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Mayo Clinic

Phase 3
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Exelixis Clinical Site #67

Phase 1
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Cancer Center at Saint Joseph's

Phase 2/3

Tampa, Florida6 trials

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Moffitt Cancer Center

Early 1
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Moffitt Cancer Center

Phase 1
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Moffitt Cancer Center

Phase 2
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Moffitt Cancer Center

Phase 1
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Moffitt Cancer Center

Phase 2
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD

Moffitt Cancer Center

Phase 2

St Louis, Missouri5 trials

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Washington University School of Medicine

Phase 1
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Washington University School of Medicine

Phase 1/2
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

Washington University School of Medicine

Phase 1
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

Washington University School of Medicine

Phase 1/2
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 1

Houston, Texas5 trials

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

MD Anderson Cancer Center

Phase 1
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

M D Anderson Cancer Center

Phase 2
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

M D Anderson Cancer Center

Phase 1/2
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

MD Anderson Cancer Center

Phase 1/2
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

M D Anderson Cancer Center

Phase 2

Los Angeles, California4 trials

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

The Angeles Clinic and Research Institute

Phase 1/2
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Los Angeles Hematology Oncology Medical Group

Phase 2/3
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Site 03

Phase 1/2
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

USC Norris Comprehensive Cancer Center

Phase 2

Atlanta, Georgia4 trials

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Emory University Hospital Midtown

Phase 2
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Emory University Hospital Midtown

Phase 2
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Emory University Hospital/Winship Cancer Institute

Phase 2
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Emory University Hospital Midtown

Phase 1

Baltimore, Maryland4 trials

A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer

Maryland Proton Treatment Center

Phase 1
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Sidney Kimmel Comprehensive Cancer Center

Phase 1
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center

Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Johns Hopkins Hospital

Phase 2

Nashville, Tennessee4 trials

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Vanderbilt-Ingram Cancer Center

Phase 2
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Vanderbilt University Medical Center

Phase 1
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Vanderbilt University/Ingram Cancer Center

Phase 1/2
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Vanderbilt University Medical Center

Early 1

Scottsdale, Arizona3 trials

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

HonorHealth Research Insisute

Phase 2/3
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic in Arizona

Phase 1
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Mayo Clinic in Arizona

Phase 2

Duarte, California3 trials

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

City of Hope Medical Center

Phase 1
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

City of Hope National Medical Center

Phase 2
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

City of Hope Medical Center

Phase 1

Orange, California3 trials

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Chao Family Comprehensive Cancer Center, University of California, Irvine

Phase 2
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Chao Family Comprehensive Cancer Center, University of California, Irvine

Phase 2
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

University of California Irvine

Phase 1/2

Mobile, Alabama2 trials

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Local Institution - 0487

Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Research Site

Phase 3

Irvine, California2 trials

Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

University of California, Irvine

Phase 2
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

City of Hope

Phase 2

La Jolla, California2 trials

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

UC San Diego Moores Cancer Center

Phase 1/2
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

University of California San Diego

Phase 2

Santa Monica, California2 trials

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

Sant P Chawla

Phase 2
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Sarcoma Oncology Research Center

Phase 1/2

New Haven, Connecticut2 trials

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Yale University

Phase 2
Saci Nivo Rela for TNBC

Yale University

Phase 1/2

Washington D.C., District of Columbia2 trials

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

Children's National Hospital

Early 1
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

Lombardi Comprehensive Cancer Center, Georgetown University

Phase 2

Miami, Florida2 trials

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

University of Miami

Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Sylvester Comprehensive Cancer Center - Miami

Phase 1/2

Chicago, Illinois2 trials

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

University of Illinois Cancer Center

Phase 1/2
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

University of Chicago Medical Center

Phase 1

Bethesda, Maryland2 trials

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

National Institutes of Health Clinical Center

Phase 2
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

National Institutes of Health Clinical Center

Phase 1

Boston, Massachusetts2 trials

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Massachusetts General Hospital Cancer Center

Phase 2
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Beth Israel Deaconess Medical Center ( Site 0107)

Phase 3

Basking Ridge, New Jersey2 trials

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 1
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities

Phase 2

New York, New York2 trials

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Icahn School of Medicine at Mount Sinai

Early 1
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

NYU Langone Health

Phase 4

Columbus, Ohio2 trials

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Ohio State University Comprehensive Cancer Center

Phase 1
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1

Philadelphia, Pennsylvania2 trials

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Fox Chase Cancer Center

Early 1
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Goodyear, Arizona1 trial

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

I-Mab Site 1016

Phase 2

Fayetteville, Arkansas1 trial

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Highlands Oncology Group - Fayetteville

Phase 3

Little Rock, Arkansas1 trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Baptist Health Medical Center - Little Rock

Phase 2/3

Berkeley, California1 trial

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Alta Bates Summit Medical Center-Herrick Campus

Phase 3

Beverly Hills, California1 trial

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Precision NextGen Oncology

Phase 1/2

Dublin, California1 trial

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Kaiser Permanente Dublin

Phase 2

Fresno, California1 trial

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

ClinRé 001-022 (Premier Cancer Care and Infusion Center)

Phase 3

Palo Alto, California1 trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Local Institution - 0178

Phase 1/2

Stanford, California1 trial

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Stanford Cancer Institute

Phase 1/2

Aurora, Colorado1 trial

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

University of Colorado Cancer Center

Phase 1/2

North Haven, Connecticut1 trial

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Yale-New Haven Hospital - Yale Cancer Center

Phase 2

West Haven, Connecticut1 trial

Repositioning Immunotherapy in VetArans With Lung Cancer

VA Connecticut Healthcare System West Haven Campus, West Haven, CT

Phase 2

Newark, Delaware1 trial

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Christiana Care Health System - Newark- Site Number : 8400011

Phase 1/2

Jacksonville, Florida1 trial

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Mayo Clinic in Florida

Phase 2

St. Petersburg, Florida1 trial

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

Johns Hopkins All Children's Hospital

Phase 1/2

Iowa City, Iowa1 trial

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

University of Iowa Health Care

Phase 1

Westwood, Kansas1 trial

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

The University of Kansas Cancer Center

Phase 3

Ann Arbor, Michigan1 trial

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

University of Michigan Comprehensive Cancer Center

Phase 1/2

Detroit, Michigan1 trial

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

Local Institution - 0011

Phase 1/2

Rochester, Minnesota1 trial

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Mayo Clinic in Rochester

Phase 2

Hackensack, New Jersey1 trial

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

John Theurer Cancer Center at Hackensack University Medical Center

Phase 1

Lancaster, Pennsylvania1 trial

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Lancaster General Hospital

Phase 2

Pittsburgh, Pennsylvania1 trial

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

UPMC Hillman Cancer Center

Phase 2

Providence, Rhode Island1 trial

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

Rhode Island Hospital

Phase 2

Salt Lake City, Utah1 trial

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Huntsman Cancer Institute

Phase 2

Seattle, Washington1 trial

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.